The FREEDOM trial is a 36-month international RCT of 7,868 postmenopausal women with osteoporosis (T-score −2.5 to −4.0) testing whether subcutaneous denosumab 60 mg every 6 months reduces fracture risk compared to placebo across vertebral, hip, and nonvertebral sites.
When your postmenopausal osteoporosis patient cannot tolerate or adhere to oral bisphosphonates, denosumab 60 mg SC every 6 months is a well-validated alternative with demonstrated fracture reduction across all major sites — but counsel patients that discontinuation leads to rapid reversal of effect and rebound vertebral fracture risk, and monitor for the rare but significant serious cellulitis signal observed in this trial.
The FREEDOM trial is a 36-month international RCT of 7,868 postmenopausal women with osteoporosis (T-score −2.5 to −4.0) testing whether subcutaneous denosumab 60 mg every 6 months reduces fracture risk compared to placebo across vertebral, hip, and nonvertebral sites.
When your postmenopausal osteoporosis patient cannot tolerate or adhere to oral bisphosphonates, denosumab 60 mg SC every 6 months is a well-validated alternative with demonstrated fracture reduction across all major sites — but counsel patients that discontinuation leads to rapid reversal of effect and rebound vertebral fracture risk, and monitor for the rare but significant serious cellulitis signal observed in this trial.